Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types.
Publication
, Journal Article
Luo, N; Mentz, RJ; O'Brien, EC
Published in: JACC Heart Fail
September 2017
Duke Scholars
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
September 2017
Volume
5
Issue
9
Start / End Page
689
Location
United States
Related Subject Headings
- Valsartan
- Tetrazoles
- Humans
- Heart Failure
- Drug Combinations
- Biphenyl Compounds
- Aminobutyrates
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Luo, N., Mentz, R. J., & O’Brien, E. C. (2017). Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. JACC Heart Fail, 5(9), 689. https://doi.org/10.1016/j.jchf.2017.07.002
Luo, Nancy, Robert J. Mentz, and Emily C. O’Brien. “Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types.” JACC Heart Fail 5, no. 9 (September 2017): 689. https://doi.org/10.1016/j.jchf.2017.07.002.
Luo N, Mentz RJ, O’Brien EC. Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. JACC Heart Fail. 2017 Sep;5(9):689.
Luo, Nancy, et al. “Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types.” JACC Heart Fail, vol. 5, no. 9, Sept. 2017, p. 689. Pubmed, doi:10.1016/j.jchf.2017.07.002.
Luo N, Mentz RJ, O’Brien EC. Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. JACC Heart Fail. 2017 Sep;5(9):689.
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
September 2017
Volume
5
Issue
9
Start / End Page
689
Location
United States
Related Subject Headings
- Valsartan
- Tetrazoles
- Humans
- Heart Failure
- Drug Combinations
- Biphenyl Compounds
- Aminobutyrates
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology